太龙药业：《药品生产许可证》换发并变更生产范围等信息

Core Viewpoint - The company has received a renewed "Drug Production License" from the Henan Provincial Drug Administration, valid until December 31, 2030, which includes changes in production scope, production lines, and entrusted production situations [1] Group 1 - The renewal of the license ensures the company's normal operations and does not significantly impact the existing production structure [1] - The company will need to apply for GMP compliance checks to resume the production of certain products [1] - There are reductions in the production lines for certain products, including the reduction of the production of three drugs, such as Berberine Hydrochloride Tablets [1] Group 2 - The current changes do not affect the company's performance for this period, but there is uncertainty regarding drug production and sales due to policy and market influences [1]